Multiple Myeloma is a incurable disease. Recently developed targeted therapy gave new hope for the patients with multiple myeloma. Velcade in combination with other agents are currently in trials for the newly diagnosed patient, we designed sequential treatment with VTD and MPT for the patients who are not transplant candidates. This would be expected to result in maximal tumor control, and thus, in maximal survival benefit, equivalent to high dose therapy with autologous transplantation in younger population
The two effective and non-cross resistant regimens, VTD and MPT, will be applied sequentially to the patients with multiple myeloma who are not transplant candidates. This would be expected to result in maximal tumor control, and thus, in maximal survival benefit, equivalent to high dose therapy with autologous transplantation in younger population
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
35
Gachon University Gil Hospital
Inchon, South Korea
Response rate of VTD induction Therapy
Time frame: 2008-02-01
Response rate of VTD/MPT maintenance therapy
Time frame: 2008-02-01
Progression free survival Overall survival of VTD/MPT
Time frame: 2008-02-01
To evaluate toxicities of VTD/MPT
Time frame: 2008-02-01
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.